Search Within

Andrew D Seidman

  1. "Body Imaging Service"
Formats
  1. Meeting Abstract (12)
  2. Journal Article (10)
  3. Conference Paper (1)
Groups
  1. Body Imaging Service (23)
  2. Breast Medicine Service (23)
  3. Department of Medicine (23)
  4. Radiology, Department of (23)
  5. Solid Tumor Oncology Division (23)
  6. Survivorship Research (23)

More Groups

People
  1. Clifford Hudis (21)
  2. Larry Norton (14)
  3. Ariadne Bach (12)
  4. Mary Ellen Moynahan (11)
  5. Violante Currie (10)
  6. Marc Gollub (8)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2013 (1)
  4. 2012 (1)
  5. 2011 (1)
  6. 2010 (1)

More Years

Publications
  1. Journal of Clinical Oncology (10)
  2. Breast Cancer Research and Treatment (3)
  3. Clinical Breast Cancer (3)
  4. International Journal of Radiation Oncology, Biology, Physics (2)
  5. Cancer Investigation (1)
  6. Cancer Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (10)
  2. Elsevier Inc. (7)
  3. Springer (3)
  4. American Association for Cancer Research (1)
  5. Informa Healthcare (1)
  6. Pergamon-Elsevier Science Ltd (1)

Results (23)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression trial - A randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Eng, J.; Yeh, R.; Girshman, J.; Das, J.; Gelblum, D.; Xu, A. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Consolidative use of radiotherapy to block (CURB) oligoprogression: Interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Shepherd, A. F.; Eng, J.; Gelblum, D.; Xu, A. J.; Namakydoust, A.; Iqbal, A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2021)

    Fulltext@MSK | Save
  • Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer
    Journal Article

    Seidman, A. D.; Conlin, A. K.; Bach, A.; Moynahan, M. E.; Lake, D.; Forero, A.; Wright, G. S.; Hackney, M. H.; Clawson, A.; Norton, L.; more...
    Clinical Breast Cancer (2013)

    Fulltext@MSK | Save
  • Tesetaxel: Activity of an oral taxane as first-line treatment in metastatic breast cancer
    Meeting Abstract

    Seidman, A. D.; Schwartzberg, L. S.; O'Shaughnessy, J.; D'Andrea, G.; Rubin, P.; Katz, S.; Danesi, H.; Itri, L.; Hudis, C.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Randomized phase II trial of weekly vs. q 2-weekly vs. q 3-weekly nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for metastatic breast cancer
    Meeting Abstract

    Seidman, A. D.; Conlin, A. K.; Bach, A.; Forero-Torres, A.; Wright, G.; Hackney, M. H.; Clawson, A.; Schofield, D.; Iglesias, J.; Hudis, C. A.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer
    Journal Article

    Conlin, A.; Seidman, A.; Bach, A.; Lake, D.; Dickler, M.; D'Andrea, G.; Traina, T.; Danso, M.; Brufsky, A.; Saleh, M.; more...
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)
    Meeting Abstract

    Conlin, A. K.; Hudis, C. A.; Bach, A.; Moynahan, M.; Lake, D.; Forero-Torres, A.; Wright, G.; Hackney, M.; Clawson, A.; Seidman, A. D.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Seidman, A. D.; Conlin, A. K.; Bach, A.; Brufsky, A. M.; Saleh, M. N.; Lake, D.; Dickler, M. N.; D'Andrea, G.; Traina, T. A.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Nanoparticle albumin-bound paclitaxel in 3 dosing schedules with bevacizumab as first line therapy for HER2-negative metastatic breast cancer: An interim safety analysis
    Meeting Abstract

    Seidman, A. D.; Conlin, A. K.; Moynahan, M. E.; Bach, A.; Troso-Sandoval, T.; Sugarman, S.; Forero, A.; Kerr, R.; Wright, G.; Hudis, C. A.
    EJC Supplements (2008)

    Fulltext@MSK | Save
  • Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report
    Meeting Abstract

    Conlin, A. K.; Seidman, A. D.; Moynahan, M. E.; Traina, T.; Mace, J. R.; Meiri, E.; Bach, A.; Edwards, C.; Hudis, C. A.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save